GAH and Tenacia announce a China commercialization partnership for ZTALMY, the first approved therapy for CDKL5 deficiency disorder.
First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. ("Tenacia") and GOLDEN AGE HEALTH ...
Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...
Morning Overview on MSN
Scientists uncover stunning proof your heart can repair itself
For decades, cardiology textbooks treated heart damage as permanent, a grim one-way street from heart attack to heart failure ...
Media ReleaseEntered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside ...
Explore new findings on drug-resistant breast cancer and how targeting cell cycle regulators may improve treatment outcomes.
Media Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January ...
This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to standard therapy extended ...
BACKGROUND: Oscillatory shear stress (OSS), resulting from disturbed blood flow, is implicated in atherosclerotic plaque formation by incompletely understood mechanisms. This study aims to elucidate ...
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Google Maps’ Gemini upgrade brings hands-free AI help to walking and cycling, offering directions, tips and local insights on the go.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results